Search results
Results from the WOW.Com Content Network
Albiglutide (trade names Eperzan in Europe and Tanzeum in the US) is a glucagon-like peptide-1 agonist (GLP-1 agonist) drug marketed by GlaxoSmithKline (GSK) for treatment of type 2 diabetes. As of 2017 it is unclear if it affects a person's risk of death. [2]
A 2020 Cochrane systematic review did not find enough evidence of reduction of all-cause mortality, serious adverse events, cardiovascular mortality, non-fatal myocardial infarction, non-fatal stroke or end-stage renal disease when comparing metformin monotherapy to meglitinide for the treatment of type 2 diabetes.
Drugs used in diabetes treat types of diabetes mellitus by decreasing glucose levels in the blood. With the exception of insulin , most GLP-1 receptor agonists ( liraglutide , exenatide , and others), and pramlintide , all diabetes medications are administered orally and are thus called oral hypoglycemic agents or oral antihyperglycemic agents.
Victoza, chemically known as liraglutide, is a once-daily injection approved for use in adults and children aged 10 or older with type 2 diabetes. The drug brought in annual sales of $1.66 billion ...
In the SURMOUNT-1 trial, Lilly gave nearly 2,000 volunteers with pre-diabetes and obesity or overweight the drug at one of three different doses and 640 people a placebo and lifestyle counseling ...
A recent study has shown that people who take SGLT-2 inhibitors for type 2 diabetes management have a 35% lower diabetes risk, overall. A diabetes drug may help prevent dementia, new research ...
Dapagliflozin is used along with diet, exercise, and usually with other glucose-lowering medications, to improve glycaemic control in adults with type 2 diabetes. . Dapagliflozin, in addition to other SGLT2-inhibitors, was shown to reduce the rate of decline in kidney function and kidney failure in non-diabetic and type 2 diabetic adults when added to the existing treatment
More than 48 million Americans 12 years or older had a substance use disorder in 2022, yet only 24 percent received treatment, according to the National Survey on Drug Use and Health. In 2021, as ...